<DOC>
	<DOCNO>NCT02701166</DOCNO>
	<brief_summary>Randomized double blind placebo control trial evaluate antipruritic effect bezafibrate patient moderate severe cholestatic itch .</brief_summary>
	<brief_title>The Effect Bezafibrate Cholestatic Itch</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Bezafibrate</mesh_term>
	<criteria>diagnosis primary biliary cholangitis primary/secondary sclerosing cholangitis define EASL clinical practice guideline cholestasis 2009 ; itch without primary dermatologic abnormality intensity score â‰¥ 5.0 cm scale 0.0 cm ( itch ) 10.0 cm ( bad itch possible ) , score twice week inclusion . Concomitant guidelinerecommended well experimental antipruritic therapy , e.g . rifampicin , opioidreceptor antagonist ( naltrexon , naloxone ) , serotoninreuptake inhibitor ( sertraline ) , ondansetron , phenobarbital , propofol , lidocaine , dronabinol , butorphanol , internal external biliary drainage , extracorporeal albumin dialysis , ultravioletB phototherapy ; NB . Topical menthol contain agent allow , well bile salt sequestrants ( colesevelam , cholestyramin ) long take least 4 hour intake study medication . Incidental use agent note patient diary , structural use note CRF ( section comedication ) ; Pregnancy , woman childbearing potential use contraception , breast feeding ; Cholestasis due obstruction require invasive desobstructive treatment within time scope study ( 5 week ) , endoscopic retrograde cholangiopancreaticography ( ERCP ) surgical removal tumor compress bile duct ; Use opiates ; Renal insufficiency ( creatinine clearance &lt; 60mL/min ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pruritus</keyword>
	<keyword>itch</keyword>
	<keyword>cholestasis</keyword>
</DOC>